HC Wainwright Predicts Nuvation Bio Q1 Earnings

Key Points

• HC Wainwright maintained a Buy rating and a $21 price target for Nuvation Bio, forecasting Q1 2027 EPS of $0.01, Q2 EPS of ($0.06), and full-year 2027 EPS of ($0.11).
• Nuvation Bio’s latest quarter missed expectations, reporting a loss of $0.15 per share versus the $0.14 consensus, though revenue of $31.69 million exceeded estimates of $27.03 million.
• The stock opened at $6.61, while analyst sentiment remained a “Moderate Buy” with an average target of $13.00; institutional investors own 61.67% of shares, and insiders sold $1.42 million of stock during the last quarter.

Nuvation Bio Inc. (NYSE:NUVB - Free Report) - Research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for shares of Nuvation Bio in a report released on Friday, August 7th. HC Wainwright analyst R. Burns forecasts that the company will earn $0.01 per share for the quarter. HC Wainwright currently has a "Buy" rating and a $21.00 target price on the stock. The consensus estimate for Nuvation Bio's current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for Nuvation Bio's Q2 2027 earnings at ($0.06) EPS and FY2027 earnings at ($0.11) EPS.

Nuvation Bio (NYSE:NUVB - Get Free Report) last released its earnings results on Thursday, August 6th. The company reported ($0.15) earnings per share for the quarter, missing analysts' consensus estimates of ($0.14) by ($0.01). The firm had revenue of $31.69 million during the quarter, compared to the consensus estimate of $27.03 million. Nuvation Bio had a negative return on equity of 46.59% and a negative net margin of 88.18%.

Several other research analysts also recently commented on NUVB. Zacks Research raised shares of Nuvation Bio from a "strong sell" rating to a "hold" rating in a research note on Monday, July 6th. B. Riley Financial reaffirmed a "buy" rating on shares of Nuvation Bio in a report on Friday. Royal Bank Of Canada upped their price target on shares of Nuvation Bio from $19.00 to $20.00 and gave the company an "outperform" rating in a research report on Friday. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Nuvation Bio in a research note on Friday, July 17th. Finally, Citigroup reiterated a "market outperform" rating on shares of Nuvation Bio in a report on Wednesday, June 10th. Eight analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, Nuvation Bio has an average rating of "Moderate Buy" and an average target price of $13.00.

Nuvation Bio Stock Up 0.1%

Shares of NUVB opened at $6.61 on Monday. Nuvation Bio has a 1 year low of $2.18 and a 1 year high of $9.75. The company has a debt-to-equity ratio of 0.96, a current ratio of 8.37 and a quick ratio of 8.14. The stock has a 50 day simple moving average of $5.76 and a two-hundred day simple moving average of $5.24. The firm has a market cap of $2.30 billion, a P/E ratio of -15.01 and a beta of 1.52.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its holdings in Nuvation Bio by 0.7% in the 4th quarter. Vanguard Group Inc. now owns 15,555,606 shares of the company's stock worth $139,378,000 after buying an additional 101,011 shares during the period. Millennium Management LLC raised its holdings in shares of Nuvation Bio by 52.4% during the first quarter. Millennium Management LLC now owns 3,774,003 shares of the company's stock valued at $6,642,000 after acquiring an additional 1,298,131 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in Nuvation Bio by 19.9% in the third quarter. Dimensional Fund Advisors LP now owns 3,321,249 shares of the company's stock worth $12,276,000 after acquiring an additional 551,508 shares during the period. Price T Rowe Associates Inc. MD boosted its holdings in Nuvation Bio by 852.2% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,708,553 shares of the company's stock valued at $24,270,000 after acquiring an additional 2,424,109 shares in the last quarter. Finally, Two Sigma Investments LP boosted its holdings in Nuvation Bio by 95.7% in the third quarter. Two Sigma Investments LP now owns 2,377,570 shares of the company's stock valued at $8,797,000 after acquiring an additional 1,162,837 shares in the last quarter. Hedge funds and other institutional investors own 61.67% of the company's stock.

Insider Activity

In other news, insider Kerry Wentworth sold 63,000 shares of the company's stock in a transaction dated Tuesday, June 23rd. The shares were sold at an average price of $6.02, for a total transaction of $379,260.00. Following the completion of the transaction, the insider directly owned 53,000 shares of the company's stock, valued at approximately $319,060. This represents a 54.31% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Philippe Sauvage sold 47,668 shares of the stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $6.01, for a total transaction of $286,484.68. Following the sale, the chief financial officer owned 12,673 shares of the company's stock, valued at approximately $76,164.73. This represents a 79.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 235,668 shares of company stock worth $1,419,495 in the last quarter. Insiders own 30.11% of the company's stock.

About Nuvation Bio

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company's pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source